Clinical trials: sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Lead sponsor (exact) Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Funder type Industry (pharma, biotech, devices)
Thyroid Cancer
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong…
- Trial name
- NCT06860971
- Testing
- AL2846 Capsules
- Where
- 35 sites in China
- Volunteers
- 144 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
To analyze radioactivity excretion and pharmacokinetics in healthy subjects after a single oral dose of [¹⁴C]TQ05105, identifying excretion routes, major metabolites, and biotransformation pathways.
- Trial name
- NCT07293390
- Testing
- TQ05105
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Trial name
- NCT07291050
- Testing
- TQB3217Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Differentiated Thyroid Cancer
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects.
- Trial name
- NCT05745363
- Testing
- AL2846 capsule
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thrombocytopenia
Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
The overall design of this clinical study is a single center, randomized, open label, single dose, two sequence, two cycle bioequivalence trial in healthy individuals under fed conditions.
- Trial name
- NCT06768619
- Testing
- Group 1: single-dose of test formulation+single-dose of reference formulation, Group 2: single-dose of reference formulation+single-dose of test formulation
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of…
- Trial name
- NCT06024915
- Testing
- TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or…
- Trial name
- NCT06851442
- Testing
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Where
- 17 sites in China
- Volunteers
- 8 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.
- Trial name
- NCT06122831
- Testing
- TQ05105 Tablets, TQB3617 Capsules
- Where
- 22 sites in China
- Volunteers
- 92 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can…
- Trial name
- NCT06682169
- Testing
- Rovadicitinib, Imatinib, Methotrexate
- Where
- 41 sites in China
- Volunteers
- 182 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Graft Versus Host Disease
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and…
- Trial name
- NCT04944043
- Testing
- TQ05105 Tablet
- Where
- 12 sites in China
- Volunteers
- 45 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
Clinical Trial of TQB3002 in Patients With Advanced Cancers
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
- Trial name
- NCT06662760
- Testing
- TQB3002 Tablets
- Where
- 11 sites in China
- Volunteers
- 150 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Dedifferentiated Liposarcoma
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.
- Trial name
- NCT05496569
- Testing
- TQB3616 capsule
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell…
- Trial name
- NCT06320080
- Testing
- TQB2223 injection, Penpulimab Injection
- Where
- 3 sites in China
- Volunteers
- 22 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Severe Asthma
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
This is a phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of TQC2731 on Annualized Asthma Exacerbation Rates(AAER) in adult subjects with…
- Trial name
- NCT05472324
- Testing
- TQC2731 injection
- Where
- 2 sites in China
- Volunteers
- 205 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker.
- Trial name
- NCT07172126
- Testing
- TQB3201 tablets
- Where
- 3 sites in China
- Volunteers
- 291 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT07147946
- Testing
- TQC3721 Suspension for inhalation
- Where
- 76 sites in China
- Volunteers
- 666 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Lung Cancer, Ovarian Cancer
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer.
- Trial name
- NCT05815862
- Testing
- AL2846 capsule
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy of TQ05105 Tablets in patients with intermediate-risk and high-risk myelofibrosis.
- Trial name
- NCT06388759
- Testing
- TQ05105 Tablets
- Where
- 6 sites in China
- Volunteers
- 9 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with renal impairment after a single dose, and to evaluate the urinary…
- Trial name
- NCT06598956
- Testing
- TQ05105
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.
- Trial name
- NCT06198751
- Testing
- 6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection
- Where
- 7 sites in China
- Volunteers
- 104 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.